ID: MRFR/HC/7028-HCR | February 2023 | Region: Global | 115 Pages
The Systemic Lupus Erythematosus Treatment Market size is projected to reach USD 2.11 Billion at a CAGR of 8.80% from 2022 to 2030.
$2.11 Billion
8.80%
North America
2022-2030
The systemic lupus erythematosus treatment market is expected to reach USD 2.11 Billion by 2030 at 8.80% CAGR during the forecast period 2022-2030. Systemic lupus erythematosus is a disease that causes inflammation in connective tissues, like the lining of blood vessels and cartilage. Systemic lupus erythematosus medication includes nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials, and corticosteroids amongst others. Early Systemic lupus erythematosus diagnosis and treatment can help to reduce the adverse effects of SLE and improve the chances of having a better life. SLE treatment currently includes administering drugs from four categories, namely corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials, and Immunosuppressive agents and immune modulators.
Systemic Lupus Erythematosus Treatment Market Influencer
Research and development for the launch of drugs, by key players, for the treatment of systemic lupus erythematosus.
Market Drivers
Market Restraints
Systemic Lupus Erythematosus Treatment Market Segmentation
By Treatment
By Route of Administration
By Distribution Channel
By Region
Systemic Lupus Erythematosus Treatment Market Key Players
Report Attribute/Metric | Details |
---|---|
Market Size | USD 2.11 Billion |
CAGR | 8.80% |
Base Year | 2021 |
Forecast Period | 2022 - 2030 |
Historical Data | 2020 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | By Treatment, Route of Administration, Distribution Channel |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Sanofi (France), Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), AstraZeneca (UK), Eli Lilly and Company (US), Bristol-Myers Squibb Company (US), Amgen Inc. (US), Anthera (US), Johnson & Johnson Services, Inc. (US) |
Key Market Opportunities | Joint ventures, strategic alliances, mergers and acquisitions and new product developments |
Key Market Drivers |
|
systemic lupus erythematosus treatment market is projected grow at approximately 8.80% CAGR during the assessment period (2022-2030).
The valuation of the global systemic lupus erythematosus treatment market is estimated to increase to USD 2.11 Billion by the end of 2030.
The Immunosuppressive agents & immune modulators segment by treatment type holds the majority shares in the global systemic lupus erythematosus treatment market.
North America holds the largest share in the global systemic lupus erythematosus treatment market, followed by Europe and the Asia Pacific, respectively.
F. Hoffmann-La Roche Ltd (Switzerland), Sanofi (France), Novartis AG (Switzerland), GlaxoSmithKline plc (UK), Pfizer Inc. (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Amgen Inc. (US), Johnson & Johnson Services, Inc. (US), and Anthera (US), are some of the major players operating in the global systemic lupus erythematosus treatment market.